Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03909477
Other study ID # ROB0043
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2022
Est. completion date December 1, 2030

Study information

Verified date June 2024
Source Western University, Canada
Contact Grace E Parraga, PhD
Phone 519-931-5777
Email gparraga@robarts.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.


Description:

This is a longitudinal study of the long-term lung health impact of cannabis smoking in adults using xenon-129 (129Xe) MRI over three years. Males and females between the ages of 18 to 85 years with a history of cannabis smoking will be screened, and those who satisfy all inclusion and exclusion criteria will undergo study visits for up to 3 years, with visits every 12 ± 3 months, for a total of up to four study visits. Each study visit will include collection of patient smoking history and vital signs. At Visit 1 and 4, 129-Xe MRI, spirometry, plethysmography for airways resistance (Raw) and lung volumes, forced oscillation technique (FOT) and multiple breath nitrogen washout (MBNW) for the lung clearance index (LCI) will all be performed pre- and post-bronchodilator. Blood will be drawn for blood eosinophil count, and sputum induction will be done to measure sputum eosinophils. A CT will also be done at Robarts Research Institute, or at University Hospital, London Health Sciences Centre next door to Robarts. Visit 2 will be a telephone call to complete questionnaires. Visit 3 will include spirometry and questionnaires only. Participants 35 years of age or older will complete a six minute walk test (6MWT) for the distance walked (6MWD), pre and post oxygen saturation, perceived dyspnea (Modified Borg Scale) and perceived exertion (Borg's rating of perceived exertion). These participants will complete the St. George's Respiratory Questionnaire (SGRQ). Participants under the age of 35 will complete Cardio Pulmonary Exercise Testing to assess exercise capacity, and the American Thoracic Society Questionnaire (ATSQ).


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 1, 2030
Est. primary completion date December 1, 2030
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature - Provision of written, informed consent prior to any study specific procedures - Males and females aged 18-85 - Current or former cannabis smoker (medicinal or recreational) with or without concurrent tobacco smoking history - Participant is able to perform reproducible pulmonary function testing (i.e. the 3 best acceptable spirograms have Forced Expiratory Volume in 1 second (FEV1) values that do not vary more than 150 millilitres) - Participant is able to perform a breathhold for 16s - FEV1 > 25% predicted - Forced Vital Capacity (FVC) > 25% predicted and >0.5 litres Exclusion Criteria: - Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material - Participant is medically unstable in the opinion of the Principal Investigator - Participant has a daytime room air oxygen saturation <90% while lying supine - Participant is unable to perform spirometry or plethysmography maneuvers - Patient is pregnant at time of enrolment - In the opinion of the investigator, patient suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia - Patient has implanted mechanically, electrically or magnetically activated device or any metal in their body, which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) - at the discretion of the MRI Technologist.

Study Design


Intervention

Diagnostic Test:
Hyperpolarized Xenon-129 MRI of the lungs
Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
Computed Tomography (CT)
Participants will undergo a CT scan of the thoracic cavity
Pulmonary Function Tests (PFTs)
Participants will have their lung function evaluated using PFTs
Six Minute Walk Test (6MWT)
Participants >35 years of age will perform the six minute walk test as a measure of exercise capacity
Cardiopulmonary exercise testing (CPET)
Participants <35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
Sputum analysis
Participants will provide a sputum sample that will be analysed for eosinophils
Blood analysis
Participants will have their blood drawn and analysed for eosinophil count.

Locations

Country Name City State
Canada Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Western University, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in airways over time Measured using Xenon-129 (129-Xe) MRI 3 years
Primary Changes in parenchyma over time Measured using Xenon-129 (129-Xe) MRI 3 years
Primary Differences in lung ventilation in cannabis smokers compared to never-smokers and tobacco smokers Measured using 129-Xe MRI 3 years
Primary Differences in perfusion in cannabis smokers compared to never-smokers and tobacco smokers Measured using 129-Xe MRI 3 years
Primary Differences in parenchyma integrity in cannabis smokers compared to never-smokers and tobacco smokers Measured using 129-Xe MRI 3 years
Primary Differences in airways between cannabis-only smokers and cannabis and tobacco smokers Measured using 129-Xe MRI 3 years
Primary Differences in parenchyma between cannabis-only smokers and cannabis and tobacco smokers Measured using 129-Xe MRI 3 years
Primary Dose-response of cannabis use to changes in airways over time Measured using 129-Xe MRI 3 years
Primary Dose-response of cannabis use to changes in parenchyma over time Measured using 129-Xe MRI 3 years
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity